Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

[News]

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

More... (http://www.news-medical.net/news/20121015/Celgene-receives-FDA-approval-for-ABRAXANE-to-treat-non-small-cell-lung-cancer.aspx)